EKTAY
Price
$5.45
Change
-$0.00 (-0.00%)
Updated
Dec 18 closing price
NEOG
Price
$11.63
Change
-$0.50 (-4.12%)
Updated
Dec 18, 04:59 PM (EDT)
104 days until earnings call
Ad is loading...

EKTAY vs NEOG

Header iconEKTAY vs NEOG Comparison
Open Charts EKTAY vs NEOGBanner chart's image
Elekta AB
Price$5.45
Change-$0.00 (-0.00%)
Volume$25.14K
CapitalizationN/A
Neogen
Price$11.63
Change-$0.50 (-4.12%)
Volume$99.55K
CapitalizationN/A
EKTAY vs NEOG Comparison Chart
Loading...
EKTAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NEOG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EKTAY vs. NEOG commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EKTAY is a Hold and NEOG is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (EKTAY: $5.45 vs. NEOG: $12.13)
Brand notoriety: EKTAY and NEOG are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EKTAY: 71% vs. NEOG: 155%
Market capitalization -- EKTAY: $3.09B vs. NEOG: $3.42B
EKTAY [@Medical Specialties] is valued at $3.09B. NEOG’s [@Medical Specialties] market capitalization is $3.42B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EKTAY’s FA Score shows that 1 FA rating(s) are green whileNEOG’s FA Score has 1 green FA rating(s).

  • EKTAY’s FA Score: 1 green, 4 red.
  • NEOG’s FA Score: 1 green, 4 red.
According to our system of comparison, EKTAY is a better buy in the long-term than NEOG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EKTAY’s TA Score shows that 3 TA indicator(s) are bullish while NEOG’s TA Score has 4 bullish TA indicator(s).

  • EKTAY’s TA Score: 3 bullish, 4 bearish.
  • NEOG’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, EKTAY is a better buy in the short-term than NEOG.

Price Growth

EKTAY (@Medical Specialties) experienced а -6.56% price change this week, while NEOG (@Medical Specialties) price change was -7.90% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.17%. For the same industry, the average monthly price growth was +1.60%, and the average quarterly price growth was -0.66%.

Reported Earning Dates

NEOG is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Medical Specialties (-4.17% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEOG($3.42B) has a higher market cap than EKTAY($3.09B). NEOG has higher P/E ratio than EKTAY: NEOG (150.80) vs EKTAY (34.01). EKTAY YTD gains are higher at: -30.695 vs. NEOG (-39.682). EKTAY has higher annual earnings (EBITDA): 2.49B vs. NEOG (189M). EKTAY has more cash in the bank: 3.27B vs. NEOG (230M). NEOG has less debt than EKTAY: NEOG (889M) vs EKTAY (6.67B). EKTAY has higher revenues than NEOG: EKTAY (16.9B) vs NEOG (919M).
EKTAYNEOGEKTAY / NEOG
Capitalization3.09B3.42B90%
EBITDA2.49B189M1,315%
Gain YTD-30.695-39.68277%
P/E Ratio34.01150.8023%
Revenue16.9B919M1,839%
Total Cash3.27B230M1,422%
Total Debt6.67B889M750%
FUNDAMENTALS RATINGS
EKTAY vs NEOG: Fundamental Ratings
EKTAY
NEOG
OUTLOOK RATING
1..100
856
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6589
PRICE GROWTH RATING
1..100
6289
P/E GROWTH RATING
1..100
523
SEASONALITY SCORE
1..100
5043

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EKTAY's Valuation (2) in the null industry is significantly better than the same rating for NEOG (96) in the Medical Specialties industry. This means that EKTAY’s stock grew significantly faster than NEOG’s over the last 12 months.

EKTAY's Profit vs Risk Rating (100) in the null industry is in the same range as NEOG (100) in the Medical Specialties industry. This means that EKTAY’s stock grew similarly to NEOG’s over the last 12 months.

EKTAY's SMR Rating (65) in the null industry is in the same range as NEOG (89) in the Medical Specialties industry. This means that EKTAY’s stock grew similarly to NEOG’s over the last 12 months.

EKTAY's Price Growth Rating (62) in the null industry is in the same range as NEOG (89) in the Medical Specialties industry. This means that EKTAY’s stock grew similarly to NEOG’s over the last 12 months.

NEOG's P/E Growth Rating (3) in the Medical Specialties industry is somewhat better than the same rating for EKTAY (52) in the null industry. This means that NEOG’s stock grew somewhat faster than EKTAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EKTAYNEOG
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
58%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
54%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 9 days ago
65%
Bullish Trend 9 days ago
69%
Declines
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
EKTAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NEOG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DHAMX17.56N/A
N/A
Centre American Select Equity Inv
AZBAX26.77N/A
N/A
Virtus Small-Cap A
GICCX12.70N/A
N/A
Goldman Sachs Intl Sm Cp Insghts C
IGMAX7.81-0.04
-0.51%
Voya Global Insights Portfolio ADV
CICEX58.86-4.90
-7.69%
American Funds Invmt Co of Amer 529E

EKTAY and

Correlation & Price change

A.I.dvisor tells us that EKTAY and SAUHY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EKTAY and SAUHY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EKTAY
1D Price
Change %
EKTAY100%
-3.88%
SAUHY - EKTAY
31%
Poorly correlated
-0.08%
SMMNY - EKTAY
29%
Poorly correlated
-0.89%
PHG - EKTAY
29%
Poorly correlated
-2.53%
GNGBY - EKTAY
26%
Poorly correlated
-2.01%
NEOG - EKTAY
26%
Poorly correlated
+2.36%
More

NEOG and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEOG has been loosely correlated with CRL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NEOG jumps, then CRL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEOG
1D Price
Change %
NEOG100%
+2.36%
CRL - NEOG
46%
Loosely correlated
-0.39%
ICUI - NEOG
44%
Loosely correlated
-1.19%
TWST - NEOG
43%
Loosely correlated
-0.06%
VCYT - NEOG
41%
Loosely correlated
-2.52%
MASS - NEOG
40%
Loosely correlated
-5.58%
More